UNSPSC 51332878: Trifluoperazine dihydrochloride

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C21H24F3N3S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6P1Y2SNF5V, chemically known as 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine dihydrochloride, but more generally known as trifluoperazine dihydrochloride, which bears US NIH Compound Identifier 5566.

European Medicines Agency schedules trifluoperazine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11288MIG. Most nations, for tariff purposes, schedule trifluoperazine dihydrochloride under HS 29343090. SMILES: CN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)C(F)(F)F.CL.CL.

UNSPSC 51332878 Trifluoperazine dihydrochloride is a Commodity code nominally covering a specific antipsychotic pharmaceutical, but recent state and local procurement activity under this code does not reflect targeted sourcing of trifluoperazine itself. Instead, the code appears to be tagged across broader pharmaceutical and medication-procurement initiatives, including naloxone distribution, generic multi-source pharmaceutical supply contracts, and pharmacy benefit program restructuring. State and local issuing bodies—county health departments, state health and human services commissions, and cooperative purchasing alliances—are using this code family to solicit suppliers for controlled-substance alternatives, emergency medications, and generic pharmaceutical distribution networks rather than for single-drug procurement. The work involves establishing supply agreements for high-volume medication delivery, compliance with FDA and Drug Supply Chain Security Act standards, and integration with authorized wholesale distribution channels.

Activity appears across Florida, Texas, and Minnesota, with the most recent opportunities reflecting a shift toward cooperative purchasing and direct-to-manufacturer contracting models. Seminole County, Florida released IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with vendors required to submit bids electronically and include shipping costs in their proposals. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit manager intermediaries. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers, with evaluations weighted heavily on price competitiveness (75 percent) and contract effective July 1, 2026.